Clinical Trial Update: A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

View source ↗

Summary

A U.S. registry study of eosinophilic esophagitis patients treated with dupilumab (DUPIXENT) as standard of care is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Eosinophilic Esophagitis (EoE) | Status: RECRUITING